Call Us Today to Make an Appointment. 1.800.734.2210

Browse > Home / Testosterone - Men / Insulin Sensitivity and Men with Heart Failure

Insulin Sensitivity and Men with Heart Failure

April 12, 2011 by  
Filed under Testosterone - Men

Leave a Comment

Researchers writing in the European Journal of Heart Failure say “Testosterone improves fasting insulin sensitivity in men with chronic heart failure and may also increase lean body mass, these data suggest a favourable effect of testosterone on an important metabolic component of chronic heart failure”

Malkin CJ, Jones TH, Channer KS. The effect of testosterone on insulin sensitivity in men with heart failure.European Journal of Heart Failure 2007 Jan;9(1):44-50.
Resistance to insulin occurs in chronic heart failure (CHF) and is related to prognosis.

Studies of testosterone in non-(CHF) males suggest that physiological testosterone therapy improves insulin sensitivity.

This was a single-blind placebo controlled crossover trial to determine the effect of testosterone replacement on insulin sensitivity in 13 men with moderate to severe CHF (ejection fraction 30.5+/-1.3). The primary outcome was the homeostatic model index (HOMA-IR) of fasting insulin sensitivity and secondary outcomes were body composition as measured by bioelectrical impedance and glucose tolerance to a standard 75 g oral glucose load. Analysis was performed on the delta values with the treatment effect of placebo compared with that of testosterone. At baseline HOMA-IR correlated with measures of body fat [% fat mass (rP=0.84, p=0.0001) and body mass index (rP=0.79, p=0.01)] but not with CHF severity.

Testosterone reduced HOMA-IR (-1.9+/-0.8, p=0.03) indicating improved fasting insulin sensitivity. Testosterone also increased total mass (+1.5+/-0.5 kg, p=0.008) and decreased body fat (-0.8+/-0.3%, p=0.02).

Testosterone improves fasting insulin sensitivity in men with CHF and may also increase lean body mass, these data suggest a favourable effect of testosterone on an important metabolic component of CHF.

Written by Dr. Marc Darrow, M.D.

Dr. Darrow is a world recognized specialist in many chronic disorders. He has been featured in national publications, and television and radio shows, for his innovative approach to medicine. As the medical director of the Darrow Wellness Institute in West Los Angeles, Dr. Darrow has helped create an age management program for those individuals interested in maintaining a youthful, healthy vigor for adults through “middle age” and well into the senior years.

Tags: , , , ,

Comments are closed.

Prolotherapy, PRP, AGE MANAGEMENT MEDICINE, and other modalities mentioned are medical techniques that may not be considered mainstream. As with any medical TREATMENT, results will vary among individuals, and there is no implication that you will HEAL OR receive the same outcome as patients herein. there could be pain or substantial risks involved. These concerns should be discussed with your health care provider prior to any treatment so that you have proper informed consent and understand that there are no guarantees to healing.
THE INFORMATION IN THIS WEBSITE IS OFFERED FOR EDUCATIONAL PURPOSED ONLY AND DOES NOT IMPLY OR GIVE MEDICAL ADVICE. THE PHOTOS USED MAY BE MODELS AND NOT PATIENTS.